Manzo Pharmaceuticals, Inc. announced that after discussions with the Food and Drug Administration, it has been determined that its long lasting lactose digestive aid, Lacto-Freedom(TM), will not need FDA approval to be released to the public. The FDA considers the probiotic to be a dietary "supplement", and therefore outside the scope of a very long and expensive FDA approval process that would be required if the treatment was deemed to be a "drug." This will greatly reduce the time to market for Lacto-Freedom and enable Manzo Pharmaceuticals to market the product to millions of people who suffer from lactose intolerance much sooner. The company is taking the necessary steps to put a small human study in place and hopes to have it off the ground in a few months.

There has been a lot of change and progress within the company recently as it has undergone a name change and a small change in corporate stock structure. The company feels the release of Lacto-Freedom could be the most important healthcare breakthrough ever for millions of lactose intolerance sufferers worldwide.